Eudragit S-100 entrapped chitosan microspheres of valdecoxib for colon cancer

J Mater Sci Mater Med. 2010 Sep;21(9):2691-9. doi: 10.1007/s10856-010-4109-2. Epub 2010 Jun 10.

Abstract

COX-2 inhibitors have demonstrated beneficial effects in colorectal cancer. The purpose of this study was to prepare and evaluate the colon specific microspheres of COX-2 inhibitors using valdecoxib as a model drug. Mucoadhesive core microspheres were prepared using chitosan as polymer and entrapped within Eudragit S 100 for colon targeting. FTIR spectrum of selected, coated microspheres showed peaks of valdecoxib at 3377, 3250, 1334 and 1155 cm(-1). XRD showed amorphous character and DSC showed depressed broad endotherm of valdecoxib at 169.07 degrees C, which may be attributed to dilution effect by the amorphous polymer. The coated microspheres were spherical with an average size of 90 mum. Storage of the microspheres at 40 degrees C/75% relative humidity for 6 months indicated no significant drug degradation. The coated microspheres did neither release the drug in acidic pH of stomach (pH 1.2) nor in small intestinal pH between 5 to 6.8, and the release started at pH 7.4, indicting perfect colonic delivery. The coated microspheres pretreated with phosphate buffer pH 7.4 for 30 min, when applied to mucosal surface of freshly excised goat colon, showed good mucoadhesion. The drug release at pH 7.4 and good mucoadhesive property of the microspheres make the system ideal for colonic delivery.

MeSH terms

  • Colonic Neoplasms / drug therapy*
  • Cyclooxygenase 2 Inhibitors / chemistry
  • Cyclooxygenase 2 Inhibitors / therapeutic use*
  • Humans
  • Isoxazoles / chemistry
  • Isoxazoles / therapeutic use*
  • Microspheres*
  • Polymethacrylic Acids / chemistry*
  • Sulfonamides / chemistry
  • Sulfonamides / therapeutic use*

Substances

  • Cyclooxygenase 2 Inhibitors
  • Isoxazoles
  • Polymethacrylic Acids
  • Sulfonamides
  • methylmethacrylate-methacrylic acid copolymer
  • valdecoxib